Latest News from ASCO in Action

Latest News from ASCO in Action

July 23, 2014

On July 23, 2014, the U.S. Food and Drug Administration (FDA) approved idelalisib (Zydelig® tablets, Gilead Sciences, Inc.) for the treatment of patients with relapsed chronic lymphocytic leukemia (CLL), in combination with rituximab, for whom rituximab alone would be considered appropriate therapy due to other co-morbidities. 

July 22, 2014

On July 29, ASCO will debut the ASCO in Action Beat, an e-newsletter specifically focused on the latest news and updates related to cancer policy from ASCO in Action.

July 11, 2014

ASCO is hearing that some oncology practices are having difficulty obtaining paclitaxel.

ASCO's ACT Network

ASCO's ACT Network

ALERT CONGRESS TODAY! Use ASCO's ACT Network to contact your elected officials on important policy issues impacting cancer care. 

ASCO Issue Backgrounders

ASCO Issue Backgrounders

ASCO offers issue backgrounders to help provide an overview of the major policy issues that impact patients with cancer and the physicians who care for them. The issue backgrounders cover topics such as reimbursement, health equity, cancer research funding, and more.

Click here to read the backgrounds and help develop your understanding of cancer policy issues.

NIH Funding Educational Series

NIH Funding Educational Series

ASCO explores the decade-long decline in federal funding for cancer research – and why this decline must be reversed. Read more here.